A Phase Ib/II Study to Investigate the Safety , PK and PD of SHR-1819 in Children and Adolescents With Moderate-to-severe Atopic Dermatitis
Latest Information Update: 06 Dec 2024
Price :
$35 *
At a glance
- Drugs SHR-1819 (Primary)
- Indications Atopic dermatitis
- Focus Adverse reactions
- Sponsors Guangdong Hengrui Pharmaceutical
- 06 Dec 2024 New trial record